Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma

International Journal of Molecular Medicine

Volumn 34, Issue 5, 2014, Pages 1225-1232

  Han, Xiao Jian ^a   Wei, Yong Fang ^a   Wan, Yu Ying ^a   Jiang, Li Ping ^a   Zhang, Jian Feng ^a   Xin, Hong Bo ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

Bioluminescence imaging; Drug delivery system; ErbB2; Gaussia luciferase; Liposome; Ovarian carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; LIPOSOME; NICKEL; RECOMBINANT PROTEIN; ERBB2 PROTEIN, HUMAN; ERBB2 PROTEIN, MOUSE; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPOSOMAL DELIVERY; MCF 7 CELL LINE; MICROSCOPE; MOLECULAR IMAGING; MOLECULAR SIZE; MOUSE; NONHUMAN; OVARY METASTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG SCREENING; GENETICS; LUMINESCENCE; METABOLISM; NEOPLASM; OVARY TUMOR; PLASMID; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIGANDS; LIPOSOMES; LUCIFERASES; LUMINESCENT MEASUREMENTS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLASMIDS; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907188390     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1922     Document Type: Article

References (35)

1. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
2. Graus-Porta D, Beerli RR, Daly JM and Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647-1655, 1997.
3. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
4. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
5. Berchuck A, Kamel A, Whitaker R, et al: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091, 1990.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
7. Kim R, Tanabe K, Uchida Y, Osaki A and Toge T: The role of HER-2 oncoprotein in drug-sensitivity in breast cancer. Oncol Rep 9: 3-9, 2002.
8. Pero SC, Shukla GS, Armstrong AL, Peterson D, Fuller SP, Godin K, Kingsley-Richards SL, Weaver DL, Bond J and Krag DN: Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int J Cancer 111: 951-960, 2004.
9. Hashizume T, Fukuda T, Nagaoka T, Tada H, Yamada H, Watanabe K, Salomon DS and Seno M: Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol Int 32: 814-826, 2008.
10. Han XJ, Sun LF, Nishiyama Y, Feng B, Michiue H, Seno M, Matsui H and Tomizawa K. Theranostic protein targeting ErbB2 for bioluminescence imaging and therapy for cancer. PLoS One 8: e75288, 2013.
11. Vaidyanath A, Hashizume T, Nagaoka T, Takeyasu N, Satoh H, Chen L, Wang J, Kasai T, Kudoh T, Satoh A, Fu L and Seno M: Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. J Cell Mol Med 15: 2525-2538, 2011.
12. Tannous BA: Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 4: 582-591, 2009.
13. Lembert N and Idahl LA: Regulatory effects of ATP and luciferin on firefly luciferase activity. Biochem J 305: 929-933, 1995.
14. Matthews JC, Hori K and Cormier MJ: Substrate and substrate analogue binding properties of Renilla luciferase. Biochemistry 16: 5217-5220, 1977.
15. Lorenz WW, McCann RO, Longiaru M and Cormier MJ: Isolation and expression of a cDNA encoding Renilla reniformis luciferase. Proc Natl Acad Sci USA 88: 4438-4442, 1991.
16. Tannous BA, Kim DE, Fernandez JL, Weissleder R and Breakefield XO: Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11: 435-443, 2005.
17. Venisnik KM, Olafsen T, Gambhir SS and Wu AM: Fusion of Gaussia luciferase to an engineered anti-carcinoembryonic antigen (CEA) antibody for in vivo optical imaging. Mol Imaging Biol 9: 267-277, 2007.
18. Feng B, Tomizawa K, Michiue H, Han XJ, Miyatake S and Matsui H: Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials 31: 4139-4145, 2010.
19. Hyodo K, Yamamoto E, Suzuki T, Kikuchi H, Asano M and Ishihara H: Development of liposomal anticancer drugs. Biol Pharm Bull 36: 703-707, 2013.
20. Oude Blenke E, Mastrobattista E and Schiffelers RM: Strategies for triggered drug release from tumor targeted liposomes. Expert Opin Drug Deliv 10: 1399-1410, 2013.
21. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, Tanizawa K and Kuroda S: Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 21: 885-890, 2003.
22. Feng B, Tomizawa K, Michiue H, Miyatake S, Han XJ, Fujimura A, Seno M, Kirihata M and Matsui H: Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 30: 1746-1755, 2009.
23. Tsutsui Y, Tomizawa K, Nagita M, Michiue H, Nishiki T, Ohmori I, Seno M and Matsui H: Development of bionanocapsules targeting brain tumors. J Control Release 122: 159-164, 2007.
24. Woodle MC and Lasic DD: Sterically stabilized liposomes. Biochim Biophys Acta 1113: 171-199, 1992.
25. Duncan R: Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688-701, 2006.
26. Jiang W, Kim BY, Rutka JT and Chan WC: Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin Drug Deliv 4: 621-633, 2007.
27. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
28. Rose PG, Piver MS, Tsukada Y and Lau TS: Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64: 1508-1513, 1989.
29. Jiang Y, Berk M, Singh LS, Tan H, Yin L, Powell CT and Xu Y: KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metastasis 22: 369-376, 2005.
30. Richter M and Zhang H: Receptor-targeted cancer therapy. DNA Cell Biol 24:271-282, 2005.
31. Haberkorn U, Markert A, Eisenhut M, Mier W and Altmann A: Development of molecular techniques for imaging and treatment of tumors. Q J Nucl Med Mol Imaging 55: 655-670, 2011.
32. Jiang W, Kim BY, Rutka JT and Chan WC: Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3: 145-150, 2008.
33. Kapp KS, Kapp DS, Poschauko J, Stücklschweiger GF, Hackl A, Pickel H, Petru E and Winter R: The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol Oncol 74: 400-407, 1999.
34. Del Vecchio S, Zannetti A, Fonti R, Pace L and Salvatore M: Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging 51: 152-163, 2007.
35. Yu MK, Park J and Jon S: Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2: 3-44, 2012.